![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication July 6, 2004.
Revised September 21, 2004.
Accepted for publication September 22, 2004.
Breast cancer resistance protein (Bcrp/Abcg2) is a new efflux transporter found at the blood-brain barrier (BBB) of humans and pigs. Since it has been hypothesized that Bcrp may act as a new type of efflux transporter at the BBB, we investigated the involvement of Bcrp in the efflux transport of typical substrates, dehydroepiandrosterone sulfate (DHEAS) and mitoxantrone, across the mouse BBB. The expression of Bcrp in mouse brain capillaries was confirmed by quantitative PCR, Western blot and immunohistochemical analysis. The role of Bcrp as an efflux transporter was evaluated using the in situ brain perfusion method in wild-type and P-gp knockout mice, with or without treatment with GF120918, an inhibitor of both Bcrp and P-gp. The increased brain uptake of [3H]DHEAS and [3H]mitoxantrone by GF120918 in wild-type and P-gp knockout mice suggested the existence of a GF120918-sensitive and P-gp independent efflux transporter for DHEAS and mitoxantrone across the BBB. However, the brain uptake of [3H]DHEAS in Bcrp knockout mice was comparable with that in wild-type mice, and the effect of GF120918 was still observed in Bcrp knockout mice. In addition, the brain uptake of [3H]mitoxantrone was also similar in wild-type and Bcrp knockout mice. These results suggest that although BCRP is expressed at the BBB it plays a minor role in active efflux transport of DHEAS and mitoxantrone out of brain and that one or more GF120918-sensitive efflux transporters distinct from BCRP or P-gp contributes to the brain efflux of DHEAS and mitoxantrone.
Key words:
Blood-brain barrier, Breast cancer resistance protein, Dehydroepiandrosterone sulfate, Efflux transporter, GF120918, Mitoxantrone
This article has been cited by other articles:
|
|
 |
|
  S.-H. Yuan, X.-F. Liang, W.-H. Jia, J.-L. Huang, M. Wei, L. Deng, L.-Z. Liang, X.-Y. Wang, and Y.-X. Zeng Molecular Diagnosis of Sentinel Lymph Node Metastases in Cervical Cancer Using Squamous Cell Carcinoma Antigen Clin. Cancer Res., September 1, 2008; 14(17): 5571 - 5578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Giri, N. Shaik, G. Pan, T. Terasaki, C. Mukai, S. Kitagaki, N. Miyakoshi, and W. F. Elmquist Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse Drug Metab. Dispos., August 1, 2008; 36(8): 1476 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Enokizono, H. Kusuhara, A. Ose, A. H. Schinkel, and Y. Sugiyama Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds Drug Metab. Dispos., June 1, 2008; 36(6): 995 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, C. Chen, and B. J. Smith Progress in Brain Penetration Evaluation in Drug Discovery and Development J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 349 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. de Vries, J. Zhao, E. Kroon, T. Buckle, J. H. Beijnen, and O. van Tellingen P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan Clin. Cancer Res., November 1, 2007; 13(21): 6440 - 6449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ando, H. Kusuhara, G. Merino, A. I. Alvarez, A. H. Schinkel, and Y. Sugiyama Involvement of Breast Cancer Resistance Protein (ABCG2) in the Biliary Excretion Mechanism of Fluoroquinolones Drug Metab. Dispos., October 1, 2007; 35(10): 1873 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Enokizono, H. Kusuhara, and Y. Sugiyama Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens Mol. Pharmacol., October 1, 2007; 72(4): 967 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takenaka, J. A. Morgan, G. L. Scheffer, M. Adachi, C. F. Stewart, D. Sun, M. Leggas, K. F.K. Ejendal, C. A. Hrycyna, and J. D. Schuetz Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution Cancer Res., July 15, 2007; 67(14): 6965 - 6972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Deeken and W. Loscher The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses Clin. Cancer Res., March 15, 2007; 13(6): 1663 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Leggas, J. C. Panetta, Y. Zhuang, J. D. Schuetz, B. Johnston, F. Bai, B. Sorrentino, S. Zhou, P. J. Houghton, and C. F. Stewart Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters In vivo. Cancer Res., May 1, 2006; 66(9): 4802 - 4807. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
